DR. JAMES MICHAEL CROWE, DDS
Dentist in Bethesda, MD

License number

Maryland 5424

Professional information

Dr. James M Crowe, Bethesda MD - DDS (Doctor of Dental Surgery)

Specialties:

Dentistry

Address:

4400 E West Hwy STE B, Bethesda 20814
(301) 656-3660 (Phone), (301) 656-3660 (Fax)

Languages:

English

James Michael Crowe, Bethesda MD

Specialties:

Dentist

Address:

4400 E West Hwy, Bethesda, MD 20814

Immunogenic Compositions Comprising Cold-Adapted Attenuated Respiratory Syncytial Virus Mutants

US Patent:

6284254, Sep 4, 2001

Filed:

May 30, 1995

Appl. No.:

8/453304

Inventors:

Brian R. Murphy - Bethesda MD
Robert M. Chanock - Bethesda MD
James E. Crowe - Chevy Chase MD
Mark Connors - Chevy Chase MD
Alan R. Davis - Wayne PA
Michael D. Lubeck - Glenmoore PA
Bernard H. Selling - Bryn Mawr PA

Assignee:

The United States of America as represented by the Department of Health and
Human Services - Washington DC

International Classification:

A61K 39155

US Classification:

4242111

Abstract:

The respiratory syncytial virus (RSV) is a major cause of lower respiratory tract disease in infants and children throughout the world. RSV is a major cause of pneumonia and bronchiolitis in infants under one year of age, and is a major cause of fatal respiratory tract disease in these infants. The treatment and prevention of RSV infection has been problematic. However, the present invention addresses some of these concerns by providing attenuated RSV strains that are suitable for inclusion in immunizing compositions. Specifically, the present invention is directed toward the introduction of growth restriction mutations into incompletely attenuated host range-restricted cold-passaged respiratory syncytial virus (cpRSV) strains by further passage of the strains at increasingly reduced temperatures to produce derivative strains which are more satisfactorily attenuated. These cold-adaptation (ca) approaches were used to introduce further attenuation in the parental RSV virus cpRSV-3131, which is incompletely attenuated in seronegative children. Mutants of the parental strain were obtained by selecting for large plaque production at reduced temperatures.

Human Neutralizing Monoclonal Antibodies To Respiratory Syncytial Virus

US Patent:

5762905, Jun 9, 1998

Filed:

Dec 10, 1993

Appl. No.:

8/162102

Inventors:

Dennis R. Burton - La Jolla CA
Carlos F. Barbas - San Diego CA
Robert M. Chanock - Bethesda MD
Brian R. Murphy - Bethesda MD
James E. Crowe - Chevy Chase MD

Assignee:

The Scripps Research Institute - La Jolla CA

International Classification:

C12N 1563, C07K 1610, C07H 2104, G01N 3353

US Classification:

424 149

Abstract:

Human monoclonal antibodies and fragments thereof which bind and neutralize respiratory syncytial virus (RSV) antigenic subgroups A and B are disclosed. Also disclosed are diagnostic and immunotherapeutic methods of using the monoclonal antibodies as well as cell lines producing the monoclonal antibodies.

Attenuated Respiratory Syncytial Virus Vaccine Compositions

US Patent:

5922326, Jul 13, 1999

Filed:

Oct 21, 1994

Appl. No.:

8/327263

Inventors:

Brian R. Murphy - Bethesda MD
Robert M. Chanock - Bethesda MD
James E. Crowe - Chevy Chase MD
Mark Connors - Chevy Chase MD

Assignee:

The United States of America, as represented by the Department of Health
& Human Services - Washington DC

International Classification:

A61K 39155, C12N 704, C12N 708

US Classification:

4242111

Abstract:

The present invention provides vaccine compositions of attenuated respiratory syncytial virus (RSV). More particularly, the attenuated virus may be a derivative of RSV which has been incompletely attenuated by cold-passage or introduction of mutations which produce virus having a temperature sensitive (ts) or cold adapted (ca) phenotype. The invention also provides methods for stimulating the immune system of an individual to induce protection against respiratory syncytial virus by administration of attenuated RSV. The invention also provides pure cultures of attenuated RS virus, wherein the virus has been more completely attenuated by the further derivatization of previously identified incompletely attenuated ts or cp mutants.